After 6pm on the 18th, at which time the 3 ASCO abstracts will become available. This - of course - we all know. Immediately following, EXEL is having this embargoed press-only participation webcast. I've been racking my brain to put this in it's appropriate context. Can anyone surmise it's significance...? Sinister, detrimental... beneficial...? Why is the press getting preferential treatment...?? Is this another Goldman PR stunt to manipulate PPS going into ASCO...?? Anyone see concerns w/ this..?? Is there an inobviate downside I'm missing..?
Here's the actual release...I may have misconstrued some of it's intent & timeline...but it still got my att'n... Sorry for the muff...??
Cabozantinib in the 2011 ASCO Annual Meeting Press Program
Data from the phase 2 randomized discontinuation trial of cabozantinib will also be featured in ASCO’s 2011 Annual Meeting Press Program, in an embargoed press-only webcast to be held on Wednesday, May 18, 2011, prior to the release of the Annual Meeting abstracts. Interested media may obtain further details at ASCO’s online Press Center (http://www.asco.org/ASCOv2/Press+Center).
Why is this going to the press prior to abstract releases? Upside? Downside?